069620.KS

Daewoong pharmaceutical Co.,Ltd [069620.KS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

069620.KS Stock Summary

Top 10 Correlated ETFs

069620.KS


Top 10 Correlated Stocks

069620.KS


In the News

069620.KS Financial details

Company Rating
Buy
Market Cap
1201.26B
Income
49.28B
Revenue
1332.28B
Book val./share
59673.48
Cash/share
13087.6
Dividend
600
Dividend %
0.58%
Employees
1.72K
Optionable
No
Shortable
Yes
Earnings
30 Oct 2023
P/E
24.26
Forward P/E
-
PEG
2.54
P/S
0.9
P/B
1.74
P/C
7.94
P/FCF
68.24
Quick Ratio
0.62
Current Ratio
1.08
Debt / Equity
0.6
LT Debt / Equity
0.21
-
-
EPS (TTM)
4.35K
EPS next Y
-
EPS next Q
-
EPS this Y
77.89%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
4.41%
Revenue Q/Q
8.62%
EPS Q/Q
55.93%
-
-
-
-
SMA20
1.04%
SMA50
13.06%
SMA100
-1.23%
Inst Own
-
Inst Trans
-
ROA
3%
ROE
8%
ROC
0.1%
Gross Margin
51%
Oper. Margin
8%
Profit Margin
4%
Payout
2%
Shs Outstand
11.51M
Shs Float
5.38M
-
-
-
-
Target Price
-
52W Range
88300.0-173000.0
52W High
-39.94%
52W Low
+17.67%
RSI
46
Rel Volume
0.33
Avg Volume
37.18K
Volume
12.26K
Perf Week
-4.24%
Perf Month
-6.14%
Perf Quarter
0.39%
Perf Half Y
-0.57%
-
-
-
-
Beta
1.01762
-
-
Volatility
1902.52%, 2313.17%
Prev Close
-0.48%
Price
103900
Change
-0.1%

069620.KS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
99.93K107.87K98.98K104.78K120.06K
Net income per share
-1.47K2.13K2.26K2.24K3.96K
Operating cash flow per share
4.6K5.58K9.47K3.63K11.09K
Free cash flow per share
-926.43725.993.87K-3.16K460.1
Cash per share
12.85K12.58K16.61K15.79K13.19K
Book value per share
47.87K50.31K51.67K52.12K57.02K
Tangible book value per share
44.4K45.65K48.44K43.37K44.57K
Share holders equity per share
47.87K50.31K51.67K52.12K57.02K
Interest debt per share
38.41K39.05K42.79K41.43K42.68K
Market cap
1914.62B1419.24B1759.46B1628.58B1711.33B
Enterprise value
2236.14B1780.07B2132.85B1998.37B2055.09B
P/E ratio
-126.3664.4972.8666.0440.51
Price to sales ratio
1.861.271.671.411.34
POCF ratio
40.3124.6417.4240.7214.48
PFCF ratio
-200.23189.442.62-46.8348.84
P/B Ratio
3.872.733.192.842.81
PTB ratio
3.872.733.192.842.81
EV to sales
2.171.62.021.731.61
Enterprise value over EBITDA
27.0621.013529.1821.23
EV to operating cash flow
47.0830.921.1249.9717.38
EV to free cash flow
-233.85237.5551.66-57.42418.91
Earnings yield
-0.010.020.010.020.02
Free cash flow yield
00.010.02-0.020
Debt to equity
0.780.760.810.780.73
Debt to assets
0.320.320.330.310.29
Net debt to EBITDA
3.894.266.135.43.55
Current ratio
1.42.011.621.141.16
Interest coverage
2.564.431.62.696.79
Income quality
-3.0824.181.323.02
Dividend Yield
00000
Payout ratio
-0.410.280.260.260.19
Sales general and administrative to revenue
0.030.020.020.020.02
Research and developement to revenue
0.110.10.110.110.13
Intangibles to total assets
0.120.130.130.160.17
Capex to operating cash flow
-1.2-0.87-0.59-1.87-0.96
Capex to revenue
-0.06-0.05-0.06-0.06-0.09
Capex to depreciation
-1.11-1.25-1.46-1.83-2.85
Stock based compensation to revenue
00000
Graham number
39.77K49.13K51.31K51.27K71.29K
ROIC
0.690.060.030.040.05
Return on tangible assets
-0.010.020.020.020.03
Graham Net
-22.17K-22.16K-25.88K-29.16K-40.31K
Working capital
148.27B264.18B201.6B64.23B76.14B
Tangible asset value
458.24B471.23B516.51B477.24B475.22B
Net current asset value
-84.37B-83.49B-143.31B-187.88B-273.15B
Invested capital
0.780.760.810.780.73
Average receivables
188.1B204.35B196.01B174.86B185.29B
Average payables
60.85B69.48B77.74B74.82B77.13B
Average inventory
188.03B183.32B175.79B174.51B191.89B
Days sales outstanding
6870.9860.6955.1655.99
Days payables outstanding
36.5744.0847.2642.5247.48
Days of inventory on hand
111.02102.07104.36105.05118.83
Receivables turnover
5.375.146.016.626.52
Payables turnover
9.988.287.728.587.69
Inventory turnover
3.293.583.53.473.07
ROE
-0.030.040.040.040.07
Capex per share
-5.53K-4.85K-5.6K-6.8K-10.63K

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
29.1K29.98K29.61K28.85K30.43K
Net income per share
1.58K1.85K-1.03K1.38K2.15K
Operating cash flow per share
1.41K2.76K4.3K2.26K2.85K
Free cash flow per share
46.5675.52915.54-576.111.13K
Cash per share
15.41K16.49K12.71K16K13.09K
Book value per share
55.35K56.87K54.93K59.51K59.67K
Tangible book value per share
44.23K45.28K42.93K46.28K47.04K
Share holders equity per share
55.35K56.87K54.93K59.51K59.67K
Interest debt per share
39.85K40.86K40.69K39.67K35.87K
Market cap
1953.72B1748.93B1776.67B1175.53B1108.23B
Enterprise value
2278.34B2064.87B2120.43B1476.53B1408.55B
P/E ratio
27.9621.33-39.0619.0711.2
Price to sales ratio
6.075.275.423.653.16
POCF ratio
125.4857.2337.3346.5833.85
PFCF ratio
3.79K2.09K175.31-182.685.34
P/B Ratio
3.192.782.921.771.61
PTB ratio
3.192.782.921.771.61
EV to sales
7.076.226.474.584.02
Enterprise value over EBITDA
57.2951.63-177.419.297.69
EV to operating cash flow
146.3367.5744.5558.543.02
EV to free cash flow
4.42K2.47K209.23-229.36108.46
Earnings yield
0.010.01-0.010.010.02
Free cash flow yield
000.01-0.010.01
Debt to equity
0.730.710.730.660.6
Debt to assets
0.30.290.290.270.25
Net debt to EBITDA
8.167.9-28.761.891.64
Current ratio
1.381.341.161.191.08
Interest coverage
-5.529.133.3917.070
Income quality
0.961.44-4.191.831.14
Dividend Yield
00000
Payout ratio
0.380-0.0700
Sales general and administrative to revenue
0.020.020.020.420.41
Research and developement to revenue
0.120.120.140.140
Intangibles to total assets
0.170.170.170.170.17
Capex to operating cash flow
-0.97-0.97-0.79-1.26-0.6
Capex to revenue
-0.05-0.09-0.11-0.1-0.06
Capex to depreciation
-1.55-3-3.7-3.1-1.82
Stock based compensation to revenue
00000
Graham number
44.33K48.68K35.63K42.97K53.73K
ROIC
0.020.0200.010.03
Return on tangible assets
0.010.02-0.010.010.02
Graham Net
-31.87K-32.71K-38.83K-38.06K-36.71K
Working capital
157.3B146.92B76.14B93.44B40.6B
Tangible asset value
489.63B501.19B475.22B517.17B541.33B
Net current asset value
-190.03B-198.14B-273.15B-251.54B-250.13B
Invested capital
0.730.710.730.660.6
Average receivables
170.82B179.63B186.77B184.97B176.44B
Average payables
85.43B91.39B89.05B95.02B98.1B
Average inventory
191.69B204.84B209.57B218.87B228.06B
Days sales outstanding
50.8848.0553.9148.4546.08
Days payables outstanding
49.8752.1945.7458.7348.24
Days of inventory on hand
112.84115.96114.48126.11122.34
Receivables turnover
1.771.871.671.861.95
Payables turnover
1.81.721.971.531.87
Inventory turnover
0.80.780.790.710.74
ROE
0.030.03-0.020.020.04
Capex per share
-1.36K-2.69K-3.38K-2.83K-1.72K

069620.KS Frequently Asked Questions

What is Daewoong pharmaceutical Co.,Ltd stock symbol ?

Daewoong pharmaceutical Co.,Ltd is a KR stock and trading under the symbol 069620.KS

What is Daewoong pharmaceutical Co.,Ltd stock quote today ?

Daewoong pharmaceutical Co.,Ltd stock price is $103900 today.

Is Daewoong pharmaceutical Co.,Ltd stock public?

Yes, Daewoong pharmaceutical Co.,Ltd is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks